Finance

Lists
DMN:FRA
Diamyd Medical AB
0,064 €
+1,92%
(+0,0012) 1D
20-ноя., 08:04:51 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for DMN...
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
135,11 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
135,11 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products. The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
CEOUlf Hannelius
Employees42
Founded1984
Headquarters-
SectorHealth Care
Industry-
Websitediamyd.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
2025-ж. ноя.
2026-ж. фев.
2026-ж. май
2026-ж. авг.
Revenue
245,00 миң
99,00 миң
70,00 миң
65,00 миң
Cost of goods sold
938,00 миң
786,00 миң
964,00 миң
73,00 миң
Cost of revenue
938,00 миң
786,00 миң
964,00 миң
73,00 миң
Research and development expenses
30,47 млн
45,09 млн
105,01 млн
-439,00 миң
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16,82 млн
18,30 млн
19,43 млн
16,28 млн
Operating expense
48,14 млн
64,34 млн
126,30 млн
16,51 млн
Total operating expenses
49,08 млн
65,12 млн
127,27 млн
16,58 млн
Operating income
-48,84 млн
-65,02 млн
-127,20 млн
-16,52 млн
Other non operating income
1,00 миң
1,00 миң
-
-1,00 миң
EBT including unusual items
-48,84 млн
-62,88 млн
-127,06 млн
-16,81 млн
EBT excluding unusual items
-48,06 млн
-62,88 млн
-127,06 млн
-16,68 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-925,00 миң
-840,00 миң
137,00 миң
-1,06 млн
Net income
-48,84 млн
-62,88 млн
-127,06 млн
-16,81 млн
Net profit margin
-19 936,33%
-63 513,13%
-181 514,29%
-25 861,54%
Earnings per share
-
-
-
-
Interest and investment income
833,00 миң
2,78 млн
1,07 млн
1,74 млн
Interest expense
-62,00 миң
-635,00 миң
-930,00 миң
-1,90 млн
Net interest expenses
771,00 миң
2,14 млн
138,00 миң
-157,00 миң
Depreciation and amortization charges
1,78 млн
1,78 млн
1,73 млн
1,73 млн
EBITDA
-47,06 млн
-63,24 млн
-125,47 млн
-14,79 млн
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору